» Articles » PMID: 32924881

MiR-331-3p Links to Drug Resistance of Pancreatic Cancer Cells by Activating WNT/β-Catenin Signal Via ST7L

Overview
Date 2020 Sep 14
PMID 32924881
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pancreatic cancer is an aggressive type of cancer with poor prognosis, short survival rate, and high mortality. Drug resistance is a major cause of treatment failure in the disease. MiR-331-3p has been reported to play an important role in several cancers. We previously showed that miR-331-3p is upregulated in pancreatic cancer and promotes pancreatic cancer cell proliferation and epithelial-to-mesenchymal transition-mediated metastasis by targeting ST7L. However, it is uncertain whether miR-331-3p is involved in drug resistance.

Methods: We investigated the relationship between miR-331-3p and pancreatic cancer drug resistance. As part of this, microRNA mimics or inhibitors were transfected into pancreatic cancer cells. Quantitative polymerase chain reaction was used to detect miR-331-3p expression, and flow cytometry was used to detect cell apoptosis. The Cell Counting Kit-8 assay was used to measure the IC50 values of gemcitabine in pancreatic cancer cells. The expression of multidrug resistance protein 1, multidrug resistance-related protein 1, breast cancer resistance protein, β-Catenin, c-Myc, Cyclin D1, Bcl-2, and Caspase-3 was evaluated by Western blotting.

Results: We confirmed that miR-331-3p is upregulated in gemcitabine-treated pancreatic cancer cells and plasma from chemotherapy patients. We also confirmed that miR-331-3p inhibition decreased drug resistance by regulating cell apoptosis and multidrug resistance protein 1, multidrug resistance-related protein 1, and breast cancer resistance protein expression in pancreatic cancer cells, whereas miR-331-3p overexpression had the opposite effect. We further demonstrated that miR-331-3p effects in drug resistance were partially reversed by ST7L overexpression. In addition, overexpression of miR-331-3p activated Wnt/β-catenin signaling in pancreatic cancer cells, and ST7L overexpression restored activation of Wnt/β-catenin signaling.

Conclusions: Taken together, our data demonstrate that miR-331-3p contributes to drug resistance by activating Wnt/β-catenin signaling via ST7L in pancreatic cancer cells. These data provide a theoretical basis for new targeted therapies in the future.

Citing Articles

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.

Dong F, Zhou J, Wu Y, Gao Z, Li W, Song Z Front Cell Dev Biol. 2025; 12:1499111.

PMID: 39882259 PMC: 11774998. DOI: 10.3389/fcell.2024.1499111.


The Impact of BMI on PCOS Patients and Transcriptome Profiling and Bioinformatic Analysis of Granulosa Cells in PCOS Patients with High and Low BMI.

Tao P, Yan X, Li Y, Wang Z Reprod Sci. 2025; .

PMID: 39821799 DOI: 10.1007/s43032-024-01783-6.


and as potential prognostic and therapeutic targets for adrenocortical carcinoma.

Situ Y, Deng L, Huang Z, Jiang X, Zhao L, Zhang J Cancer Biol Ther. 2024; 25(1):2428469.

PMID: 39545598 PMC: 11572284. DOI: 10.1080/15384047.2024.2428469.


Exosomal miR-331-3p derived from chemoresistant osteosarcoma cells induces chemoresistance through autophagy.

Meng C, Yang Y, Feng W, Ma P, Bai R J Orthop Surg Res. 2023; 18(1):892.

PMID: 37993925 PMC: 10666460. DOI: 10.1186/s13018-023-04338-8.


Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer.

Wei L, Sun J, Wang X, Huang Y, Huang L, Han L Front Cell Dev Biol. 2023; 11:1226639.

PMID: 37560164 PMC: 10407809. DOI: 10.3389/fcell.2023.1226639.


References
1.
Kirikoshi H, Katoh M . Expression of ST7R (ST7-like, ST7L) in normal tissues and cancer. Int J Oncol. 2002; 21(1):193-6. View

2.
Takamori H, Kanemitsu K, Hirota M, Ikeda O, Tanaka H, Beppu T . Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. Ann Surg Oncol. 2010; 18(4):1110-5. DOI: 10.1245/s10434-010-1384-6. View

3.
Zhuang L, Wang X, Wang Z, Ma X, Han B, Zou H . MicroRNA-23b functions as an oncogene and activates AKT/GSK3β/β-catenin signaling by targeting ST7L in hepatocellular carcinoma. Cell Death Dis. 2017; 8(5):e2804. PMC: 5520730. DOI: 10.1038/cddis.2017.216. View

4.
Tung M, Lin P, Cheng Y, Wu D, Yeh S, Chen C . Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2. Oncotarget. 2016; 7(22):32362-74. PMC: 5078019. DOI: 10.18632/oncotarget.8708. View

5.
Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View